July 30 (Reuters) - Johnson & Johnson JNJ.N :
* SINGLE DOSE OF JOHNSON & JOHNSON COVID-19 VACCINE CANDIDATE DEMONSTRATES ROBUST PROTECTION IN PRE-CLINICAL STUDIES
* J&J - FIRST-IN-HUMAN PHASE 1/2A CLINICAL TRIAL NOW UNDERWAY IN UNITED STATES AND BELGIUM
* J&J - PHASE 3 CLINICAL TRIAL EXPECTED TO COMMENCE IN SEPTEMBER
* J&J - STUDY PUBLISHED IN NATURE SHOWS J&J'S INVESTIGATIONAL SARS-COV-2 VACCINE ELICITS A STRONG IMMUNE RESPONSE THAT PROTECTS AGAINST SUBSEQUENT INFECTION
* J&J -TO EMPHASIZE REPRESENTATION OF POPULATIONS THAT HAVE BEEN DISPROPORTIONATELY IMPACTED BY PANDEMIC AS IT DESIGNS, IMPLEMENTS COVID-19 PHASE 3 TRIAL
* J&J - DATA SHOW INVESTIGATIONAL ADENOVIRUS SEROTYPE 26 (AD26) VECTOR-BASED VACCINE ELICITED ROBUST IMMUNE RESPONSE AS DEMONSTRATED BY "NEUTRALIZING ANTIBODIES"
* J&J - PHASE 1/2A TRIAL WILL EVALUATE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF AD26.COV2.S IN OVER 1,000 HEALTHY ADULTS
* J&J - PLANNING ALSO IS UNDERWAY FOR A PHASE 2A STUDY IN NETHERLANDS, SPAIN AND GERMANY AND A PHASE 1 STUDY IN JAPAN
* J&J - COMPANY ALSO IS PLANNING TO START A PARALLEL PHASE 3 CLINICAL TRIAL OF A TWO-DOSE REGIMEN VERSUS PLACEBO
* J&J - OBJECTIVE TO START A PIVOTAL PHASE 3 CLINICAL TRIAL OF SINGLE VACCINE DOSE VERSUS PLACEBO IN SEPTEMBER, PENDING INTERIM DATA OF PHASE 1 AND 2 TRIALS
* J&J - JANSSEN COVID-19 CLINICAL TRIAL PROGRAM, INCLUDING PHASE 1/2A CLINICAL TRIAL & PHASE 3 CLINICAL TRIAL PROGRAM, WILL EVALUATE ONE- AND TWO-DOSE REGIMENS OF AD26.COV2.S IN PARALLEL STUDIES
* J&J -DATA SHOW INVESTIGATIONAL AD26 VECTOR-BASED VACCINE PREVENTED SUBSEQUENT INFECTION, PROVIDED COMPLETE/NEAR-COMPLETE PROTECTION IN LUNGS FROM VIRUS IN NHPS